Number: CALGB S1207 Principal Investigator: Naughton, Michael
Title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (S1207)
Phase: III Disease Site: Breast, Female
Participating Site(s):
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
Contact: 800-600-3606 or

The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without your cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is a drug currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced or metastatic kidney cancer or breast cancer. It is considered investigational which means it is not approved by the FDA for non-metastatic breast cancer patients. In this study you will get hormone treatment with either everolimus or with placebo (a pill with no medication). The combination of hormone-treatment and everolimus is considered investigational in patients with breast cancer.
More Information: link
Internal Protocol Documents (requires Siteman administrative database password)